Impact of alogliptin on coronary flow reserve evaluated by magnetic resonance imaging

Trial Profile

Impact of alogliptin on coronary flow reserve evaluated by magnetic resonance imaging

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Alogliptin (Primary) ; Glimepiride
  • Indications Angina pectoris; Coronary artery disease; Myocardial infarction; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 18 Nov 2013 Status changed from recruiting to completed.
    • 29 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top